Subscribe to our newsletter

Corrona to deliver cutting-edge real world evidence research on Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis at the Annual European Congress of Rheumatology (EULAR 2016)

CorEvitas is now part of Thermo Fisher Scientific. Read More.

SOUTHBOROUGH, MA (June 8, 2016) — Corrona, a leader in real world evidence and consulting in the auto-immune field, will be represented by 13 clinical researchers who will be showcasing their research at the Annual European Congress of Rheumatology (EULAR 2016) to be held June 8-11 in London, UK. The presentations represent the efforts of 654 practicing rheumatologists in the US who, over the last 15 years, have collected longitudinal randomized controlled trial quality clinical data on patients with rheumatic diseases. In particular, 2 abstracts were accepted for podium presentations and 13 as posters, 3 of which will be highlighted on poster tours. These efforts add to Corrona’s growing number of scientific publications in peer-reviewed journals, with over 300 abstracts and 80 manuscripts.

“The Corrona team appreciates that the continued data collection efforts of our rheumatology investigators have provided the foundation for our research programs in areas such as comparative effectiveness and safety of novel therapies.” — Jeff Greenberg, MD, MPH, Chief Scientific Officer, Corrona, LLC.

Work presented at the meeting will be derived from Corrona’s rheumatoid arthritis and psoriatic arthritis/spondyloarthritis registries. The podium presentations will focus on the impact of rheumatoid arthritis disease activity on infection risk and explore biomarkers’ ability to predict response to biologic medications. Other topics being explored in the rheumatoid arthritis patient population include: trends in disease activity and treatment patterns, delays in treatment acceleration, outcomes related to a treat to target strategy, the influence of comorbidities, and a comparative effectiveness evaluation of disease modifying anti-rheumatic drugs. In psoriatic arthritis/spondyloarthritis, presentations focus on: characterization of unique patient subgroups, treatment patterns, evaluating biologic medication persistency, and rebounding of symptoms following achievement of low disease activity and biologic discontinuation.


About Corrona

Corrona was founded in 2001 by leading physicians dedicated to advancing and improving the care of patients with chronic autoimmune diseases. Its mission is to advance research and improve the quality of patient care through world-class observational cohorts. Corrona provides longitudinal clinical data, patient reported measures, and research results to all biopharmaceutical companies with an interest in autoimmune diseases. Corrona data analysis has provided a rich framework in which to explore topics such as comparative effectiveness, post market safety reporting, and commercial applications. Corrona is advised by experienced academic and clinical physicians throughout the country with a wide range of expertise.

For any questions contact us at or call us at (508) 408-5435.